Increasing prevalence of clostridium related disease and growing global geriatric population is expected to serve as a high impact rendering driver for the growth of clostridium diagnostics market over the forecast period. Furthermore, changing lifestyles, growing healthcare infrastructure, technological advancements such as artificial intelligence, alinia and automation is expected to boost market growth over the forecast period. Aforementioned, factors help in the diagnosis and treatment of clostridium disease. With changing lifestyle people are becoming prone towards the disease, due to which clostridium bacteria are becoming more resistant towards the medicines.
The Clostridium diagnostics market is segmented on the basis of technology, types, and end-use. On the basis of technology, the market is bifurcated into, diagnostic tests and emerging diagnostic technologies. Further diagnostic tests are classified as counterimmunoelectrophoresis, fluorescent-antibody assays and polymerase chain reactions. Counterimmunoelectrophoresis is one of the most commonly used diagnostic procedures to detect the nature of the bacteria and how they are functioning. Emerging diagnostic technologies are further classified as, monoclonal antibodies, DNA probes, differential light scattering, immunoassays, artificial intelligence, microcomputers & automation, flow cytometry, liposomes, MRI, chromatography, and gel microdroplets. Among these DNA probes which are also known as DNA hybridization held the largest market share as of 2013. This process is used to detect DNA sequence, type of protein, and gene of the DNA. Key factors attributing to its large share include that this process is cost-effective, rapid, and simpler.
Clostridium difficile, clostridium botulinum, clostridium tetani, clostridium sordellii, and clostridium perfringens are the types of clostridium diagnostics analyzed in the scope of the study. Among these diagnostics, clostridium difficile held the majority of the market in 2013. Key factors for its large share include increased usage of antibiotics, which increases the chances of getting infected towards this disease. On the basis of end-use, the market is segmented into, commercial/private labs, hospitals, public health labs, and physician offices. Commercial/private labs emerged as the most lucrative end-use market and are expected to grow rapidly over the forecast period. Extensive use and availability of clostridium diagnostics devices in the labs have served as the high impact rendering driver for this segment.
Geographically, the clostridium diagnostics market is studied with respect to North America, Europe, Asia Pacific, and RoW. North America and Europe are major centers for clostridium diagnostics owing to the presence of technologically updated systems, high expenditure in cardiac research & development programs, increased government funding, and high patient awareness levels. The growing economies in Asia Pacific such as India and China are expected to witness lucrative growth during the forecast period owing to the rising healthcare expenditure, and the growing prevalence of clostridium.
Key players operating in clostridium diagnostics market include Beckman Coulter Inc., Abbott Laboratories, Johnson & Johnson Services Inc., Biochem Pharmaceutical Industries Ltd., Siemens Healthcare, F. Hoffmann-La Roche Ltd and Olympus Corporation.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.